Caxton Associates LP Sells 2,218 Shares of Exelixis, Inc. (NASDAQ:EXEL)

Caxton Associates LP reduced its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL) by 6.2% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 33,508 shares of the biotechnology company’s stock after selling 2,218 shares during the quarter. Caxton Associates LP’s holdings in Exelixis were worth $1,116,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Coppell Advisory Solutions LLC bought a new position in Exelixis during the fourth quarter worth $25,000. USA Financial Formulas bought a new stake in shares of Exelixis during the 4th quarter worth about $32,000. Principal Securities Inc. grew its stake in Exelixis by 62.8% in the 4th quarter. Principal Securities Inc. now owns 967 shares of the biotechnology company’s stock valued at $32,000 after buying an additional 373 shares during the last quarter. Kestra Investment Management LLC bought a new position in Exelixis in the 4th quarter valued at about $39,000. Finally, UMB Bank n.a. lifted its position in Exelixis by 68.4% during the fourth quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company’s stock worth $45,000 after acquiring an additional 553 shares during the last quarter. 85.27% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of equities analysts have recently weighed in on the company. Barclays increased their target price on Exelixis from $25.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 13th. Oppenheimer downgraded Exelixis from an “outperform” rating to a “market perform” rating and dropped their target price for the stock from $41.00 to $33.00 in a report on Friday, January 24th. Guggenheim reissued a “buy” rating and issued a $42.00 target price on shares of Exelixis in a research report on Wednesday, February 12th. Stifel Nicolaus raised their price target on shares of Exelixis from $30.00 to $36.00 and gave the stock a “hold” rating in a research report on Wednesday, February 12th. Finally, Wells Fargo & Company reissued a “market outperform” rating on shares of Exelixis in a report on Thursday, April 17th. Two research analysts have rated the stock with a sell rating, six have assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Exelixis currently has an average rating of “Moderate Buy” and a consensus price target of $37.59.

Exelixis Stock Performance

Exelixis stock opened at $39.84 on Tuesday. The stock has a fifty day moving average of $37.00 and a 200-day moving average of $35.20. The stock has a market capitalization of $10.98 billion, a P/E ratio of 22.51, a price-to-earnings-growth ratio of 1.13 and a beta of 0.25. Exelixis, Inc. has a 52 week low of $20.14 and a 52 week high of $40.26.

Exelixis (NASDAQ:EXEL) last posted its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing analysts’ consensus estimates of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. On average, research analysts forecast that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Insider Buying and Selling at Exelixis

In other news, Director Mary C. Beckerle sold 12,210 shares of the business’s stock in a transaction dated Friday, February 14th. The stock was sold at an average price of $34.88, for a total transaction of $425,884.80. Following the sale, the director now directly owns 30,406 shares in the company, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Patrick J. Haley sold 52,636 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The shares were sold at an average price of $36.98, for a total transaction of $1,946,479.28. Following the completion of the transaction, the executive vice president now owns 303,310 shares of the company’s stock, valued at approximately $11,216,403.80. This trade represents a 14.79 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 141,851 shares of company stock worth $5,236,046 over the last quarter. Corporate insiders own 2.85% of the company’s stock.

Exelixis Company Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.